CLDX
Celldex Therapeutics·NASDAQ
--
--(--)
Market Open: --
--
--(--)
Pre-Market: --
Signals Analysis
Bullish signal 3
Bearish signal 6
Stock Price Surged Significantly
Consensus Rating "Sell"
Ample Liquidity
High Gross Profit Margin
Significant Revenue Decline
Significant Net Income Decline
RSI Overbought
EPS Below Expectations
Revenue Below Expectations
Key Stats
0.0000DAY`S RANGE0.0000
0.000052 WK RANGE0.0000
0.0000
0.0000
--
--
--
--
--
--
--
--
--
--
--
--
--
--
0.0000
0.0000
0.0000
0.0000
About CLDX
Celldex Therapeutics, Inc.
A clinical stage biotechnology company that developing vaccines for cancer and infectious and inflammatory diseases
Perryville III Building, 53 Frontage Road, Suite 220, Hampton, New Jersey 08827
--
Celldex Therapeutics, Inc., is incorporated in Delaware. The Company is a biopharmaceutical company dedicated to exploring the science of mast cell biology and developing therapeutic antibodies that have the ability to engage the human immune system and directly affect key pathways to improve the lives of patients with severe inflammation, allergies, autoimmune and other devastating diseases. The company's drug candidates include monoclonal and bispecific antibodies designed to address mast cell-mediated diseases for which existing treatments are inadequate.
Company Financials
EPS
CLDX has released its 2025 Q3 earnings. EPS was reported at -1.01, versus the expected -0.89, missing expectations. The chart below visualizes how CLDX has performed over recent quarters, highlighting trends in earnings surprises.
Forecast
Wall Street Opinions
Price Target
Volume Profile
Trade Flow Insight
Seasonals
Community Forum
Loading...
Related News
No articles available
